- Home
- FNGR vs CUE Comparison
FNGR vs CUE Comparison
Compare FNGR & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FNGR
- CUE
- Stock Information
- Founded
- FNGR 2016
- CUE 2014
- Country
- FNGR Singapore
- CUE United States
- Employees
- FNGR N/A
- CUE N/A
- Industry
- FNGR Computer Software: Prepackaged Software
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- FNGR Technology
- CUE Health Care
- Exchange
- FNGR Nasdaq
- CUE Nasdaq
- Market Cap
- FNGR 68.3M
- CUE 77.3M
- IPO Year
- FNGR N/A
- CUE 2018
- Fundamental
- Price
- FNGR $1.18
- CUE $1.31
- Analyst Decision
- FNGR
- CUE Strong Buy
- Analyst Count
- FNGR 0
- CUE 5
- Target Price
- FNGR N/A
- CUE $5.00
- AVG Volume (30 Days)
- FNGR 535.3K
- CUE 406.9K
- Earning Date
- FNGR 01-14-2025
- CUE 03-10-2025
- Dividend Yield
- FNGR N/A
- CUE N/A
- EPS Growth
- FNGR N/A
- CUE N/A
- EPS
- FNGR N/A
- CUE N/A
- Revenue
- FNGR $33,570,107.00
- CUE $9,532,000.00
- Revenue This Year
- FNGR $260.03
- CUE $73.11
- Revenue Next Year
- FNGR N/A
- CUE $11.02
- P/E Ratio
- FNGR N/A
- CUE N/A
- Revenue Growth
- FNGR N/A
- CUE 149.53
- 52 Week Low
- FNGR $1.03
- CUE $0.45
- 52 Week High
- FNGR $3.96
- CUE $2.93
- Technical
- Relative Strength Index (RSI)
- FNGR 35.93
- CUE 52.47
- Support Level
- FNGR $1.10
- CUE $1.21
- Resistance Level
- FNGR $1.27
- CUE $1.75
- Average True Range (ATR)
- FNGR 0.09
- CUE 0.18
- MACD
- FNGR 0.02
- CUE 0.00
- Stochastic Oscillator
- FNGR 40.00
- CUE 45.00
About FNGR FingerMotion Inc.
FingerMotion Inc is engaged in the provision of mobile payment and recharge services in the Chinese market. The company business line includes Telecommunications Products and Services; Value Added Products and Services; Short Message Services (SMS) and Multimedia Messaging Services (MMS); a Rich Communication Services (RCS) platform; Big Data Insights; and a Video Games Division (inactive). It principally earns revenue by providing mobile payment and recharge services to customers of telecommunications companies in China.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.